Leukemia Research
Volume 33, Issue 12 , Pages 1643-1649 , December 2009

WT1 monitoring in core binding factor AML: Comparison with specific chimeric products

  • Adriana Lasa

      Affiliations

    • Laboratori d́Hematologia, Hospital de la Santa Creu I Sant Pau, Avda Sant Antoni M. Claret, 167, 08025 Barcelona, Spain
    • ,
  • Maite Carricondo

      Affiliations

    • Laboratori d́Hematologia, Hospital de la Santa Creu I Sant Pau, Avda Sant Antoni M. Claret, 167, 08025 Barcelona, Spain
    • ,
  • Camino Estivill

      Affiliations

    • Laboratori d́Hematologia, Hospital de la Santa Creu I Sant Pau, Avda Sant Antoni M. Claret, 167, 08025 Barcelona, Spain
    • ,
  • Elena Bussaglia

      Affiliations

    • Laboratori d́Hematologia, Hospital de la Santa Creu I Sant Pau, Avda Sant Antoni M. Claret, 167, 08025 Barcelona, Spain
    • ,
  • Ignasi Gich

      Affiliations

    • Servei d́Epidemiologia, Hospital de la Santa Creu I Sant Pau, Avda Sant Antoni M. Claret, 167, 08025 Barcelona, Spain
    • ,
  • Salut Brunet

      Affiliations

    • Servei d́Hematologia Clínica, Hospital de la Santa Creu I Sant Pau, Avda Sant Antoni M. Claret, 167, 08025 Barcelona, Spain
    • ,
  • Anna Aventin

      Affiliations

    • Laboratori d́Hematologia, Hospital de la Santa Creu I Sant Pau, Avda Sant Antoni M. Claret, 167, 08025 Barcelona, Spain
    • ,
  • Jorge Sierra

      Affiliations

    • Servei d́Hematologia Clínica, Hospital de la Santa Creu I Sant Pau, Avda Sant Antoni M. Claret, 167, 08025 Barcelona, Spain
    • ,
  • Josep F. Nomdedéu

      Affiliations

    • Laboratori d́Hematologia, Hospital de la Santa Creu I Sant Pau, Avda Sant Antoni M. Claret, 167, 08025 Barcelona, Spain
    • Corresponding Author InformationCorresponding author at: Sevei d́Hematologia (Laboratori), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Avda Sant Antoni M. Claret, 167, 08025 Barcelona, Spain. Tel.: +34 932919000x2424; fax: +34 932919192.

Received 29 January 2009 ,Revised 27 March 2009 ,Accepted 30 March 2009.

References 

  1. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukaemia—a Europe Against Cancer program. Leukemia. 2003;17:2318–2357
  2. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell. 1990;60:509–520
  3. Hohenstein P, Hastie ND. The many facets of the Wilms’ tumour gene, WT1. Hum Mol Genet. 2006;15:196–201
  4. Keilholz U, Menssen HD, Gaiger A, Menke A, Oji Y, Oka Y, et al. Wilms’ tumour gene 1 (WT1) in human neoplasia. Leukemia. 2005;19:1318–1323
  5. Yang L, Han Y, Saurez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia. 2007;21:868–876
  6. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002;16:2115–2121
  7. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84:3071–3079
  8. Barragan E, Cervera J, Bolufer P, Ballester S, Martin G, Fernandez P, et al. Prognostic implications of Wilms’ tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica. 2004;89:926–933
  9. Garg M, Moore H, Tobal K, Liu Yin JA. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol. 2003;123:49–59
  10. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood. 2003;101:1698–1704
  11. Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients—results from a single-centre study. Br J Haematol. 2004;125:590–600
  12. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T, et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia. 2005;19:1416–1423
  13. Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C, et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol. 2006;24:1507–1515
  14. Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic J, et al. Real-time quantitative PCR (RQ-PCR) detection of minimal residual disease (MRD) by optimized WT1 assay to enhance risk stratification in acute myeloid leukemia (AML): a European Leukemia Net study. Blood. 2007;110:[Abs 542]
  15. Perea G, Lasa A, Aventin A, Domingo A, Villamor N, Queipo de llano MP, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics t(8;21) and inv(16). Leukemia. 2006;20:87–94
  16. Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG, Zhang DE. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol. 2001;21:5577–5590
  17. Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol. 2003;21:1988–1995
  18. King-Underwood L, Pritchard-Jones K. Wilms’ tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood. 1998;91:2961–2968
  19. Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J, et al. Mutation of the Wilms’ Tumor 1 Gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2008;26:5429–5435
  20. Nyvold CG, Stentoft J, Braendstrup K, Melsvik D, Moestrup SK, Juhl-Christensen C, et al. Wilms’ tumor 1 mutation accumulated during therapy in acute myeloid leukemia: biological and clinical implications. Leukemia. 2006;20:2051–2054
  21. Summers K, Stevens J, Kakkas I, Smith M, Smith LL, Macdougall F, et al. Wilms’ tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia. 2007;21:550–551
  22. Valk PJM, Verhaak RGW, Beijen MA, Erpelinck CAJ, van Doorn-Khosrovani SBVW, Boer JM, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617–1628
  23. Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H, et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms’ tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol. 2002;116:409–420
  24. Bruening W, Gros P, Sato T, Stanimir J, Nakamura Y, Housman D, et al. Analysis of the 11p13 Wilms’ tumor suppressor gene (WT1) in ovarian tumors. Cancer Invest. 1993;11:393–399
  25. Oji Y, Yano M, Nakano Y, Abeno S, Nakatsuka S, Ikeba A, et al. Overexpression of the Wilms’ tumor gene WT1 in esophageal cancer. Anticancer Res. 2004;24:3103–3108
  26. Oji Y, Yamamoto H, Nomura M, Nakano Y, Ikeba A, Nakatsuka S, et al. Overexpression of the Wilms’ tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci. 2003;94:712–717
  27. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997;89:1405–1412
  28. Boublikova L, Kalinova M, Ryan J, Quinn F, O’Marcaigh A, Smith O, et al. Wilms’ tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia. 2006;20:254–263
  29. Loeb DM, Korz D, Katsnelson M, Burwell EA, Friedman AD, Sukumar S. Cyclin E is a target of WT1 transcriptional repression. J Biol Chem. 2002;277:19627–19632
  30. Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S, et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood. 2006;107:3303–3312
  31. Ommen HB, Nyvold CG, Braendstrup K, Andersen BL, Ommen IB, Hasle H, et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol. 2008;141:782–791
  32. Cilloni D, Gottardi E, Fava M, Messa F, Carturan S, Busca A, et al. Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection. Blood. 2003;102:773–774

PII: S0145-2126(09)00173-8

doi: 10.1016/j.leukres.2009.03.046

Leukemia Research
Volume 33, Issue 12 , Pages 1643-1649 , December 2009

Article Tools

* Image Usage & Resolution